Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Feb 4;19(2):jjae122.
doi: 10.1093/ecco-jcc/jjae122.

The Groupe d'Etude sur les Affections Inflammatoires Digestives (GETAID): 40 Years of a Family Story in Inflammatory Bowel Disease

David Laharie  1 , Lucine Vuitton  2 , Arnaud Bourreille  3 , Yoram Bouhnik  4 , Jean-Frédéric Colombel  5 , Edouard Louis  6 , Mathurin Fumery  7   8 , Charlotte Mailhat  9 , Jean-Yves Mary  10 , Laurent Peyrin-Biroulet  11
Affiliations
Free article
Review

The Groupe d'Etude sur les Affections Inflammatoires Digestives (GETAID): 40 Years of a Family Story in Inflammatory Bowel Disease

David Laharie et al. J Crohns Colitis. .
Free article

Abstract

The Groupe d'Etude sur les Affections Inflammatoires Digestives (GETAID) was founded in Paris in 1983 by Professor Robert Modigliani and colleagues. From the beginning, the aim of this international (France, Belgium, and Switzerland), multicenter, French-speaking group was to address clinical questions raised by patients or physicians in their daily practice or the inflammatory bowel disease community, by focusing on clinical research on treatments through randomized controlled trials, prospective cohorts, and cross-sectional studies, quantifying the severity of various facets of the disease when necessary for these studies. This very innovative approach has contributed to the advancement of knowledge in inflammatory bowel diseases by publishing more than 120 original articles in peer-reviewed journals throughout the GETAID's 40-year history, most of them in top publications in gastroenterology and hepatology journals. In this paper, we will see what GETAID's contribution has been over the last 4 decades and review the reasons for its success and forthcoming challenges.

Keywords: Crohn’s disease; GETAID; clinical trial; inflammatory bowel disease; ulcerative colitis.

PubMed Disclaimer